[Serum levels of 25(OH)D3 in patients with prostate cancer compared to healthy men]

Przegl Lek. 2013;70(11):926-32.
[Article in Polish]

Abstract

Prostate cancer (CaP) is one of the most common cancers in men. On the basis of international and Polish epidemiological data it is estimated that is the second leading cause of death from cancer. These data tend to look for underlying causes such a high incidence. Detected in 1990, the relationship between UV radiation and the reduction of mortality rate due to CaP gave rise to the search for effects of vitamin D, in CaP. The aim of this study was to evalu ate the concentration of 25(OH)D3 in patients treated for prostate cancer (CaP) compared to the control group of healthy men, and attempt to assess the relationship 25(OH)D3 shortage of CaP incidence and degree of its clinical advancement.

Material and methods: The study included 42 men, aged from 42 to 86 years (average age 66.14+/-8.92 years) treated between 2005-2013 in śCO due to prostate cancer. The control group consisted of 40 healthy men aged from 42 to 78 years (average age 63.17+/-9.02) in whom CaP and other cancer disease were excluded. Patients treated for CaP were divid ed into two groups depending on the severity of the cancer being evaluated by the TNM scale. Group 1 consisted of 11 patients with low severity of CaP-T1, group 2 -31 patients with higher tumor stage (T2+T3+T4). In all patients, serum 25(OH)D3 was marked in venous blood collected in the morning.

Results: The concentration of 25(OH)D3 in the group of patients with CaP occured in 80.94. There was no statistically significant difference between patients 25(OH)D3 concentra tions of CaP and control group (p = 0.3756). In both subgroups of patients with CaP showed no statistically significant difference 25(OH)D3 concentra tions (p = 0.5672), depending on the tumor advancement stage (according to TNM).

Conclusions: The majority of tested patients with prostate cancer were low concentrations of vitamin D3. There were no significant differences in concentrations of vitamin D3 in the group of patients with CaP and in the control group. Based on the analysis no relationship between the 25(OH)D3 concentration and the stage of CaP was showed, too.

Publication types

  • Controlled Clinical Trial
  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood*
  • Cholecalciferol / blood*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / pathology
  • Reference Values

Substances

  • Biomarkers, Tumor
  • Cholecalciferol